The new deal comes as Carvykti manufacturing problems continue and 2seventy dials down Abecma expectations.

Novartis and Gracell place further bets on shortened production times, with Bristol waiting in the wings.

First-in-human clinical trial initiations include yet another KRAS G12C inhibitor, and an ADC against PD-L1.

The upcoming ASH conference will feature rival datasets from inhibitors of Menin, KIT, EZH1/2, BTK, BET, BCR/ABL and more.

Arcellx climbs 19%, but the most significant Car-T presentation at ASH might not even be in oncology.

Assets targeting PSMA and KRAS G12V, plus another gamma-delta Car-T therapy, feature among recently disclosed first-time clinical trial entrants.